Abstract
Background
Botulinum toxin type A (BTX-A) must be injected in the intramuscular area to exert its paralytic effect. The durability of the BTX-A effect varies in different patients, and this fact can result from different locations of the drug injection, for example, the muscle peripheral area (perimuscular). This study aimed to evaluate whether a difference exists in the effect duration of the muscle paralysis between intramuscular and perimuscular injections of BTX-A.
Methods
This study used 18 male New Zealand rabbits divided into two groups (A and B) based on the location of the BTX-A injection. The group A animals received 10 units of BTX-A diluted with 0.1 ml of normal saline injected perimuscularly. The group B animals received the same dosage injected in the intramuscular area of the left masseter muscle. An electroneurophysiologic study was performed 1 week before the experiment for all the animals, then repeated 1, 4, and 8 weeks after the toxin injection.
Results
The amplitude values recorded in the masseter muscle were significantly lower in both groups throughout the study than the physiologic amplitude. The comparison between groups A and B did not show any statistically significant amplitude variations throughout the 8 weeks.
Conclusion
No significant difference in the neuromuscular blockade induced by botulinum toxin type A was observed between injections into the muscle peripheral area and intramuscular injections.
Similar content being viewed by others
References
Ahn KY, Park MY, Park DH, Han DG: Botulinum toxin A for the treatment of facial hyperkinetic wrinkle lines in Koreans. Plast Reconstr Surg 105:778–784, 2000
Aminoff MJ: Eletrodiagnosis in clinical neurology. Churchill Livingstone: United States of America, 1999
Brin MF: Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 6:S146–S68, 1997
Carruthers A, Carruthers J: Update on the botulinum neurotoxins. Skin Therapy Lett 6:1–2, 2001
Dyck T: Peripheral neuropathy. Vol. 1. Saunders: Mexico, p. 453, 1993
Kessler KR, Skutta M, Benecke R: Long-term treatment of cervical dystonia with botulinum toxin A: Efficacy, safety, and antibody frequency. J Neurol 246:265–274, 1999
Kim HS, Hwang JH, Jeong ST, Lee YT, Lee PK, Suh Y, Shim JS: Effect of muscle activity and botulinum toxin dilution volume on muscle paralysis. Dev Med Child Neurol 45:200–206, 2003
Klein AW, MD: The therapeutic potential of botulinum toxin. Dermatol Surg 30:452–455, 2004
O’Brien CF: Injection techniques for botulinum toxin using eletromyography and electrical stimulation. Muscle Nerve 20(Suppl 6):S176–S180, 1997
Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H: A double-blind, randomized, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neural Neurosung Psychiatry 64:6–12, 1998
Peker T, Turgut HB, Gulekon N, Anil A: Demonstration of nerve distribution of the masticatory muscles in rabbits (oryctolagus cuniculus). Anat Histol Embriol 30:225–229, 2001
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Campos, J.H., Oliveira, L.B., Queiroz, T.O. et al. Comparison Between Intramuscular and Perimuscular Injections of Botulinum Toxin Type A. Aesth Plast Surg 30, 700–703 (2006). https://doi.org/10.1007/s00266-005-0221-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00266-005-0221-y